Phluence vs TailorMed (2026)
Both work on medication access, and they are bought from opposite ends. Phluence sells agentic AI to pharmaceutical manufacturers: action agents for eligibility and coverage, an access agent that assembles patient level data, enrollment and reverification, and Benefit Sentinel, which watches accumulators, maximizers and duplicate 340B rebates for the brand. TailorMed sells mainly to health systems, oncology practices and pharmacies: it finds financially at risk patients, matches them to assistance programs and automates enrollment, and it also sells digital programs to manufacturers. A brand team buys Phluence. A provider's financial navigation team buys TailorMed.
- Built for the manufacturer's hub and commercial team, with enrollment, reverification and bridge to coverage conversion in one platform.
- Benefit Sentinel protects a brand's gross to net by monitoring accumulator, maximizer and duplicate rebate programs.
- Positioned against the cost of a staffed hub call center, the comparison a manufacturer will actually make.
- It works inside the provider's workflow on live record data, finding patients at financial risk before a bill arrives.
- Five product lines, from the navigator platform and a patient self serve product to a service with human navigators.
- It reports $7.4 billion in assistance secured, with business associate terms and a security attestation named.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Phluence and TailorMed are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Phluence | TailorMed |
|---|---|---|
| Primary category | Healthcare Administrative Automation | Healthcare Administrative Automation |
| Founded | 2015 | 2016 |
| Headquarters | San Francisco, California | New York, New York, United States |
| Website | phluence.com | tailormed.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Phluence sells agentic AI to pharmaceutical manufacturers for patient services and commercialization. Its platform combines a library of action agents (eligibility, alternate coverage, pharmacy and custom agents), an access agent that uses tokenization to assemble patient-level data from records, pharmacy claims and registries, and a longitudinal data layer.
Source: AI Health Index, September 2026
Medication access and financial navigation platform that identifies financially at risk patients, matches them against a large network of financial assistance and manufacturer programs, and automates enrollment inside health system workflows using live EHR data.
Source: AI Health Index, September 2026
Questions buyers ask
How do Phluence and TailorMed work with the EHR?
For Phluence, the home page describes an in-EHR pipeline to reach patients upstream, and the platform page says the access agent connects to hospital records, pharmacy claims, patient registries, case management solutions and wearable data.
The Core page says the platform is deeply integrated with health system IT, keeps patient, prescription and program data in sync via HL7 and FHIR, the TailorMed API or SFTP, and populates program forms from live EHR data, and it verifies benefits through a clearinghouse. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 23, 2026. No vendor pays for placement.
How are Phluence and TailorMed priced and sold?
In Phluence's case, enterprise pharma agreements arranged through sales, typically scoped to patient volume and program complexity.
For TailorMed, the company monetizes on several sides at once: a care team platform sold to providers, a patient facing product, a tech enabled service arm, and separately digital solutions sold to life sciences companies to improve access and time to therapy across its network. A provider is buying from a company that is also selling to the manufacturers whose assistance programs the platform matches patients into. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 23, 2026. No vendor pays for placement.
How do Phluence and TailorMed handle patient data?
With Phluence, the home page sells "first party data generation": agentic patient engagement collects data during every interaction so brands can spot benefit, adherence and dropout trends, and an in-EHR and digital ad pipeline to capture consented patients and drive volume to programs.
The privacy notice covers patients whose data reaches TailorMed through its customers, and states general handling: encryption in transit and at rest, access limited to a small number of authorized staff under confidentiality commitments, retention for as long as needed to provide the services, and a security program said to comply with HIPAA and HITECH. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 23, 2026. No vendor pays for placement.
What evidence is published for Phluence and TailorMed?
For Phluence, the home page shows AstraZeneca, GSK, Biogen, Arcutis and Braeburn logos under "The Company We Keep" and calls its reverification outreach market-proven, but publishes no enrollment volumes, completion rates, cycle times or cost figures on the home or platform pages. The company traces to Lifelink Systems, founded in 2015, and Precision AQ made a strategic investment in 2025.
With TailorMed, the Complete page reports a 44 percent increase in program approvals and 49 percent fewer accounts receivable days on assistance claims. A named customer, Highlands Oncology Group, reports a 35 percent increase in patients assisted and $1.3 million in copay assistance claimed in a year, and 28 days to return on investment. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 23, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
TailorMed sells to providers and to manufacturers across the same network, so a provider should ask how manufacturer relationships affect which programs are shown to patients. Phluence publishes no security attestation and nothing on where it runs, which matters for a product assembling patient level data.
Neither publishes a price or how its models are governed. Ask Phluence how its data assembly is consented, and ask TailorMed what its AI assistant decides without a navigator.